Europe's drug regulator starts safety review of anemia drugs

04/28/2007 | MarketWatch

The European Medicines Agency says it is reviewing anemia drugs from Amgen, Roche Holding and Shire PLC to see if they increase the risk of heart and cancer problems. In the meantime, the agency recommended confining the drugs to their indicated use, for treating anemia. The agency says it also is cooperating on a review of Johnson & Johnson's Eprex, sold as Procrit in the U.S.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY